경구 고분자 제제 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 적응증별, 최종사용자별, 지역별

Oral Macromolecular Formulation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 6,853,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,655,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,544,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 경구 고분자 제제 시장 규모는 눈부신 성장을 달성하고 있으며, 2024년 판매는 1,800만 달러에 달할 것으로 보이고 있습니다. 이 시장은 연간 평균 성장률(CAGR)이 7%로 견고하게 추이하며, 2031년말에는 추정 평가액이 약 2,800만 달러에 달할 것으로 예측되고 있습니다.

경구 약물전달은 고형 제제의 잠재력을 포함하여 보존 기간 연장, 지속적인 분포, 면역 반응 강화 등의 장점으로 인해 가장 바람직한 경로로 부상하고 있습니다.

주사 바늘로 인한 손상, 통증, 바늘에 찔리는 부상 등 주사와 관련된 많은 위험은 경구용 고분자 제제로 줄일 수 있습니다. 미국에서는 매년 약 385,000건의 예리한 부상이 의료 종사자들 사이에서 발생하고 있으며, 보다 안전한 대안의 중요성이 강조되고 있습니다. 특히 소아 환자들은 주사로 인한 불편함 때문에 경구용 제제에 대한 수요가 높습니다.

경구 투여는 비침습성, 환자 순응도, 사용 편의성 등으로 인해 가장 보편적인 약물전달 방법이 되었습니다. 경구 투여는 노약자나 몸이 약한 환자들에게 특히 중요하며, 다른 사람의 도움 없이 스스로 약물을 투여할 수 있습니다.

경구용 고분자 제제는 비용 효율성이 높기 때문에 특히 저소득 지역에서 큰 수요가 있습니다. 경구용 고분자 제제를 전문으로 하는 연구자와 수탁 제조업체는 참신하고 실용적인 1회 투여 제제를 제공함으로써 환자의 삶을 단순화하기 위해 노력하고 있습니다.

당뇨병 환자는 인슐린 요법을 필요로 할 수 있으므로 세계에서 당뇨병 증가는 경구용 고분자 제제에 대한 수요를 주도하고 있습니다. 인슐린과 같은 경구용 고분자 제제는 환자에게 불편하고 까다로울 수 있는 정맥 투여에 비해 잠재적인 이점을 제공합니다.

제약회사들은 효소와 산에 의한 분해를 극복하기 위해 생물학적 제제의 경구 투여를 강화하는 다양한 방법을 적극적으로 모색하고 있습니다. 경구용 고분자 제제의 흡수는 생리적 장벽에 직면해 있으며, 많은 고분자는 소화 효소에 의해 빠르게 분해되기 쉽습니다. 위장의 pH도 약물 흡수에 영향을 미칩니다.

미국 시장은 기술 발전, 특허 승인 증가, 약물전달에 대한 나노기술 적용에 대한 지역적 연구로 인해 성장하고 있습니다. 독일 시장은 새로운 약물전달 시스템에 초점을 맞춘 연구개발 활동이 활발해지면서 성장세를 이어갈 것으로 예상됩니다.

세계의 경구 고분자 제제 시장에 대해 조사했으며, 시장의 개요와 적응증별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 경쟁 동향등을 제공하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아의 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 경구 고분자 제제 시장 전망, 2018-2031년

• 세계의 경구 고분자 제제 시장 전망, 적응증별, 금액(100만 달러), 2018-2031년
• 세계의 경구 고분자 제제 시장 전망, 최종사용자별, 금액(100만 달러), 2018-2031년
• 세계의 경구 고분자 제제 시장 전망, 지역별, 금액(100만 달러), 2018-2031년

제4장 북미의 경구 고분자 제제 시장 전망, 2018-2031년

제5장 유럽의 경구 고분자 제제 시장 전망, 2018-2031년

제6장 아시아태평양의 경구 고분자 제제 시장 전망, 2018-2031년

제7장 라틴아메리카의 경구 고분자 제제 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 경구 고분자 제제 시장 전망, 2018-2031년

제9장 경쟁 구도

• 제조업체와 최종사용자별 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁 대시보드
• 기업 개요
  • Catalent, Inc
  • Diabetology Ltd
  • UPM Pharmaceuticals

제10장 부록

KSA

영문 목차

영문목차

The global Oral Macromolecule Formulation Market is experiencing remarkable growth, with revenues reaching US$ 18 million in 2024. Market analysts anticipate a steady Compound Annual Growth Rate (CAGR) of 7%, propelling the market to an estimated valuation of approximately US$ 28 million by the end of 2031.

Oral Delivery: The Preferred Route

Oral drug delivery has emerged as the most desirable route due to its advantages, including the potential for solid formulations with extended shelf life, continuous distribution, and enhanced immune response.

The numerous risks associated with injections, such as needle-related injuries, pain, and needle stick injuries, can be mitigated by oral macromolecule formulations. Approximately 385,000 sharp injuries occur among healthcare workers in the US each year, highlighting the importance of safer alternatives. Pediatric patients, in particular, have a high demand for oral formulations due to the discomfort associated with injections.

Growing Preference for Oral Administration

Oral administration has become the most popular method of drug delivery due to its non-invasiveness, patient compliance, and ease of use. It is especially crucial for elderly and physically fragile individuals, enabling self-administration of medications without the need for assistance.

Affordability and Accessibility

Oral macromolecule formulations are in significant demand, particularly in low-income regions, owing to their cost-effectiveness. Researchers and contract manufacturers specializing in oral macromolecule formulations are dedicated to simplifying patients' lives by offering novel and practical single-unit dosage forms.

Diabetes and Oral Macromolecular Formulations

The global rise in diabetes has driven the demand for oral macromolecular formulations, as diabetic patients may require insulin therapy. The oral formulation of biomolecules like insulin offers potential advantages over intravenous administration, which can be uncomfortable and challenging for patients.

Market Growth Drivers

Introduction of Novel Drug Delivery Systems: Pharmaceutical manufacturers are actively exploring various methods to enhance the oral administration of biologics, aiming to overcome enzymatic and acidic breakdown.

Challenges in Market Growth

Drawbacks and Poor Absorption: The absorption of oral macromolecule formulations faces physiological barriers, and many macromolecules are susceptible to rapid degradation by digestive enzymes. Gastric pH can also impact drug absorption.

Booming U.S. Market

The United States market is experiencing growth due to technological advancements, increased patent approvals, and regional research on nanotechnology applications for drug delivery.

Lucrative Market in Germany

Germany's market is set to advance with growing R&D activities focused on novel drug delivery systems.

China's Research Funding

The National Natural Science Foundation of China has funded various studies on the novel oral delivery of protein and peptide drugs, aligning with the booming market for these pharmaceuticals.

Competitive Landscape

Top pharmaceutical companies are forming strategic alliances with providers of oral macromolecule formulations, and the global market is expected to expand due to the rising demand for pharmaceutical outsourcing.

Key Companies Covered:

• Catalent, Inc
• Diabetology Ltd
• UPM Pharmaceuticals

Market Segmentation

Indication:

• Inflammatory Bowel Disorder

Crohn's Disease

Ulcerative Colitis

• Diabetes
• Others

End User:

• Biopharmaceutical Companies
• Academic and Research Institutes

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Oral Macromolecular Formulation Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Oral Macromolecular Formulation Market Outlook, 2018 - 2031

• 3.1. Global Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Inflammatory Bowel Disorder
      • 3.1.1.1.1. Crohn's Disease
      • 3.1.1.1.2. Ulcerative Colitis
    • 3.1.1.2. Diabetes
    • 3.1.1.3. Others
• 3.2. Global Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Biopharmaceutical Companies
    • 3.2.1.2. Academic and Research Institutes
• 3.3. Global Oral Macromolecular Formulation Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

• 4.1. North America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Inflammatory Bowel Disorder
      • 4.1.1.1.1. Crohn's Disease
      • 4.1.1.1.2. Ulcerative Colitis
    • 4.1.1.2. Diabetes
    • 4.1.1.3. Others
• 4.2. North America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Biopharmaceutical Companies
    • 4.2.1.2. Academic and Research Institutes
  • 4.2.2. BPS Analysis/Market Attractiveness Analysis
• 4.3. North America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. U.S. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 4.3.1.2. U.S. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.1.3. Canada Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 4.3.1.4. Canada Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Oral Macromolecular Formulation Market Outlook, 2018 - 2031

• 5.1. Europe Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Inflammatory Bowel Disorder
      • 5.1.1.1.1. Crohn's Disease
      • 5.1.1.1.2. Ulcerative Colitis
    • 5.1.1.2. Diabetes
    • 5.1.1.3. Others
• 5.2. Europe Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Biopharmaceutical Companies
    • 5.2.1.2. Academic and Research Institutes
  • 5.2.2. BPS Analysis/Market Attractiveness Analysis
• 5.3. Europe Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1.2. Germany Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1.3. U.K. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1.4. U.K. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1.5. France Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1.6. France Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1.7. Italy Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1.8. Italy Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1.9. Turkey Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1.10. Turkey Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1.11. Russia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1.12. Russia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1.13. Rest of Europe Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1.14. Rest of Europe Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Oral Macromolecular Formulation Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Inflammatory Bowel Disorder
      • 6.1.1.1.1. Crohn's Disease
      • 6.1.1.1.2. Ulcerative Colitis
    • 6.1.1.2. Diabetes
    • 6.1.1.3. Others
• 6.2. Asia Pacific Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Biopharmaceutical Companies
    • 6.2.1.2. Academic and Research Institutes
  • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
• 6.3. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1.2. China Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1.3. Japan Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1.4. Japan Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1.5. South Korea Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1.6. South Korea Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1.7. India Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1.8. India Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1.9. Southeast Asia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1.10. Southeast Asia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1.11. Rest of Asia Pacific Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1.12. Rest of Asia Pacific Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

• 7.1. Latin America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Inflammatory Bowel Disorder
      • 7.1.1.1.1. Crohn's Disease
      • 7.1.1.1.2. Ulcerative Colitis
    • 7.1.1.2. Diabetes
    • 7.1.1.3. Others
• 7.2. Latin America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Biopharmaceutical Companies
    • 7.2.1.2. Academic and Research Institutes
  • 7.2.2. BPS Analysis/Market Attractiveness Analysis
• 7.3. Latin America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 7.3.1.2. Brazil Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1.3. Mexico Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 7.3.1.4. Mexico Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1.5. Argentina Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 7.3.1.6. Argentina Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1.7. Rest of Latin America Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 7.3.1.8. Rest of Latin America Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Oral Macromolecular Formulation Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Inflammatory Bowel Disorder
      • 8.1.1.1.1. Crohn's Disease
      • 8.1.1.1.2. Ulcerative Colitis
    • 8.1.1.2. Diabetes
    • 8.1.1.3. Others
• 8.2. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Biopharmaceutical Companies
    • 8.2.1.2. Academic and Research Institutes
  • 8.2.2. BPS Analysis/Market Attractiveness Analysis
• 8.3. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 8.3.1.2. GCC Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1.3. South Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 8.3.1.4. South Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1.5. Egypt Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 8.3.1.6. Egypt Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1.7. Nigeria Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 8.3.1.8. Nigeria Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1.9. Rest of Middle East & Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
    • 8.3.1.10. Rest of Middle East & Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Manufacturer vs by End User Heatmap
• 9.2. Company Market Share Analysis, 2023
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. Catalent, Inc
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. Diabetology Ltd
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. UPM Pharmaceuticals
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료